| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$1,435,800 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
8,704 |
9,538 |
26,327 |
202,744 |
| Total Sell Value |
$986,699 |
$1,086,171 |
$3,399,099 |
$29,455,215 |
| Total People Sold |
2 |
4 |
12 |
19 |
| Total Sell Transactions |
3 |
5 |
21 |
74 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Miller Michael Patrick |
EVP, US Commercial |
• – – |
2018-04-13 |
4 |
AS |
$157.49 |
$31,498 |
D/D |
(200) |
27,481 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2018-04-10 |
4 |
AS |
$155.00 |
$604,345 |
D/D |
(3,899) |
19,517 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2018-04-02 |
4 |
AS |
$150.01 |
$150,010 |
D/D |
(1,000) |
293,542 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2018-03-15 |
4 |
AS |
$151.22 |
$105,854 |
D/D |
(700) |
39,165 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2018-03-14 |
4 |
AS |
$151.12 |
$30,224 |
D/D |
(200) |
27,681 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2018-03-09 |
4 |
AS |
$150.00 |
$150,000 |
D/D |
(1,000) |
294,542 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2018-03-06 |
4 |
AS |
$142.06 |
$163,998 |
D/D |
(1,152) |
39,865 |
|
- |
|
| Treacy Paul |
SVP, Technical Operations |
• – – |
2018-03-06 |
4 |
S |
$141.47 |
$84,030 |
D/D |
(594) |
18,641 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2018-03-05 |
4 |
D |
$143.39 |
$92,917 |
D/D |
(648) |
27,881 |
|
- |
|
| Smith Karen L. |
EVP, R&D and CMO |
• – – |
2018-03-05 |
4 |
D |
$143.39 |
$92,917 |
D/D |
(648) |
28,474 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2018-03-05 |
4 |
D |
$143.39 |
$614,856 |
D/D |
(4,288) |
295,542 |
|
- |
|
| Mcgill Iain |
SVP, Europe & Rest of World |
• – – |
2018-03-05 |
4 |
D |
$143.39 |
$88,041 |
D/D |
(614) |
22,048 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2018-03-05 |
4 |
D |
$143.39 |
$193,290 |
D/D |
(1,348) |
41,017 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2018-03-05 |
4 |
D |
$143.39 |
$177,660 |
D/D |
(1,239) |
38,247 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2018-03-05 |
4 |
D |
$143.39 |
$43,304 |
D/D |
(302) |
23,416 |
|
- |
|
| Treacy Paul |
SVP, Technical Operations |
• – – |
2018-03-02 |
4 |
S |
$139.62 |
$122,446 |
D/D |
(877) |
19,235 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
37,000 |
299,830 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,200 |
23,718 |
|
- |
|
| Treacy Paul |
SVP, Technical Operations |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,600 |
20,112 |
|
- |
|
| Swisher Daniel N Jr |
President and COO |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
18,000 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,400 |
42,365 |
|
- |
|
| Mcgill Iain |
SVP, Europe & Rest of World |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
22,662 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,400 |
39,486 |
|
- |
|
| Smith Karen L. |
EVP, R&D and CMO |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
29,122 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
28,529 |
|
- |
|
881 Records found
|
|
Page 20 of 36 |
|
|
0.37 (0.34%) 
